Abstracts

THE ELUSIVE SOURCE OF HIV-1 REBOUND AFTER TREATMENT INTERRUPTION

Identifying the source of viral rebound during a monitored analytical treatment interruption (ATI) would reveal potential targets for cure strategies. Therefore, we examined the genetic composition of proviral DNA in different subsets from participants on antiretroviral therapy and compared this to rebounding virus after an ATI. Eleven participants underwent a monitored ATI and were sampled…

HIV POSTTREATMENT CONTROL DESPITE PLASMA VIRAL EVOLUTION AND DUAL INFECTION

HIV post-treatment controllers (PTCs) serve as models for sustained HIV remission. These individuals frequently have early HIV rebound before viral control and subsequent periods of intermittent low-level viremia. Little is known about the viral composition during these periods of viremia. We extracted longitudinal plasma HIV RNA from PTCs and post-treatment non-controllers (NCs) from AIDS Clinical…

EVALUATING BIOMARKERS FOR HIV REBOUND DURING TREATMENT INTERRUPTION

Validated biomarkers to evaluate HIV-1 cure strategies are currently lacking, therefore requiring analytical treatment interruption (ATI) in study participants, potentially impacting their health. Here we assessed these patients safety concerns by evaluating viral reservoir size in blood and inflammatory levels in the brain. Furthermore, restriction factor (RF) expression levels and cell-associated (CA) HIV-1 RNA transcripts were…

HIV DIRECTLY INFECTS RESTING MEMORY CD4 T CELLS

The establishment of the latent HIV reservoir in resting memory CD4 T cells occurs early in infection. Resting CD4 T cells are more difficult to infect than activated CD4 T cells. Therefore, the HIV reservoir is thought to form when HIV infects a few activated CD4 T cells that are resting down. Furthermore, HIV encodes…

CHARACTERIZATION OF CD8+ TRM TOWARD THE CONTROL OF THE HIV RESERVOIR IN CERVIX

In tissues, resident memory CD8+T cells (TRM) are most likely necessary to eliminate remaining cellular HIV-1 reservoirs. However, TRM signature includes expression of molecules associated to exhausted phenotypes during chronic viral infections. Here we addressed the functional capacity of CD8+TRM from the cervical mucosa of HIV-infected women on ART to determine the most effective phenotypes…

VIRAL REBOUND KINETICS FOLLOWING SINGLE AND COMBINATION IMMUNOTHERAPY FOR HIV/SIV

HIV infection can be treated but not cured with antiretroviral therapy, motivating the development of new therapies that instead target host immune responses. Three such immunotherapies were recently tested in non-human primates – a TLR7-agonist, therapeutic vaccine (Ad26/MVA), and broadly-neutralizing antibody (PGT121) – and cured a subset of animals by preventing or controlling viral rebound…